The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | SGN35-027: Brentuximab vedotin with nivolumab, doxorubicin, and dacarbazine in HL
Existing trials have shown brentuximab vedotin, a CD30-directed antibody-drug conjugate (ADC), with vinblastine, as well as nivolumab monotherapy to have good efficacy and safety profiles in patients with Hodgkin lymphoma. Ian Flinn, MD, PhD, Tennessee Oncology, Nashville, TN, provides an overview of the trial design and rationale of the open-label, Phase II SGN35-027 trial (NCT03646123), which will investigate brentuximab vedotin in combination with nivolumab, doxorubicin, and dacarbazine in patients with newly diagnosed patients with early-stage Hodgkin lymphoma. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
